Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery

Drug Discovery Today

Volumn 23, Issue 3, 2018, Pages 519-533

  Ahmad, Gulzar ^a   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

CELLS; CRISPR-CAS9 SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SCREENING; EPIGENETICS; GENE EDITING; GENE FUNCTION; GENE KNOCKOUT; GENE STRUCTURE; GENE TARGETING; GENETIC MANIPULATION; HUMAN; MALIGNANT NEOPLASM; MOUSE MODEL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TRANSPLANTATION; ANIMAL; ANIMAL MODEL; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; GENETICS; GENOME; PROCEDURES;

ANIMALS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; DRUG DISCOVERY; GENE EDITING; GENOME; HUMANS; MODELS, ANIMAL;

EID: 85041190079     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2018.01.014     Document Type: Review

References (107)

1. Wang, T., et al. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343 (2014), 80–84.
2. Carroll, D., Genome engineering with targetable nucleases. Annu. Rev. Biochem. 83 (2014), 409–439.
3. Malina, A., et al. Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev. 27 (2013), 2602–2614.
4. Ishino, Y., et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 169 (1987), 5429–5433.
5. Mojica, F.J., et al. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol. Microbiol. 36 (2000), 244–246.
6. Bolotin, A., et al. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 151 (2005), 2551–2561.
7. Jinek, M., et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821, 10.1126/science.1225829 Epub 2012 Jun 28.
8. Doench, J.G., et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32 (2014), 1262–1267.
9. Zhang, X.H., et al. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol. Ther. Nucleic Acids, 4, 2015, e264.
10. Park, J., et al. Digenome-seq web tool for profiling CRISPR specificity. Nat. Methods 14 (2017), 548–549.
11. Tsai, S.Q., et al. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat. Methods 14 (2017), 607–614.
12. Schaefer, K.A., et al. Unexpected mutations after CRISPR-Cas9 editing in vivo. Nat. Methods 14 (2017), 547–548.
13. Ran, F.A., et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154 (2013), 1380–1389.
14. Kawamura, N., et al. CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells. Oncotarget 6 (2015), 22361–22374.
15. Maddalo, D., et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516 (2014), 423–427.
16. Chen, S., et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160 (2015), 1246–1260.
17. Patel, S.J., et al. Identification of essential genes for cancer immunotherapy. Nature 548 (2017), 537–542.
18. Konermann, S., et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517 (2015), 583–588.
19. Gilbert, L.A., et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159 (2014), 647–661.
20. Choi, P.S., Meyerson, M., Targeted genomic rearrangements using CRISPR/Cas technology. Nat. Commun., 5, 2014, 3728.
21. Lagutina, I.V., et al. Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease. PLoS Genet., 11, 2015, e1004951.
22. Chiou, S.H., et al. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes Dev. 29 (2015), 1576–1585.
23. Kannan, K., et al. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E1272–7, 10.1073/pnas.1501735112 Epub 2015 Mar 2.
24. Torres, R., et al. Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat. Commun., 5, 2014, 3964.
25. Konermann, S., et al. Optical control of mammalian endogenous transcription and epigenetic states. Nature 500 (2013), 472–476.
26. Chen, B., et al. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155 (2013), 1479–1491.
27. Tanenbaum, M.E., et al. A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159 (2014), 635–646.
28. Yin, H., et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32 (2014), 551–553.
29. Wu, Y., et al. Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells. Cell Res. 25 (2015), 67–79.
30. Ousterout, D.G., et al. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat. Commun., 6, 2015, 6244.
31. Song, B., et al. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system. Stem Cells Dev. 24 (2015), 1053–1065.
32. Schwank, G., et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13 (2013), 653–658.
33. Smith, C., et al. Efficient and allele-specific genome editing of disease loci in human iPSCs. Mol. Ther. 23 (2015), 570–577.
34. An, M.C., et al. Polyglutamine disease modeling: epitope based screen for homologous recombination using CRISPR/Cas9 system. PLoS Curr. 6 (2014), 1–19, 10.1371/currents.hd.0242d2e7ad72225efa72f6964589369a [PMC free article] [PubMed].
35. Wang, P., et al. CRISPR/Cas9-mediated heterozygous knockout of the autism gene CHD8 and characterization of its transcriptional networks in cerebral organoids derived from iPS cells. Mol. Autism, 8, 2017, 11.
36. Kordasiewicz, H.B., et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74 (2012), 1031–1044.
37. Srikanth, P., et al. Genomic DISC1 Disruption in hiPSCs Alters Wnt Signaling and Neural Cell Fate. Cell Rep. 12 (2015), 1414–1429.
38. Hu, W., et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 11461–11466.
39. Platt, R.J., et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159 (2014), 440–455.
40. Xiao-Jie, L., et al. CRISPR-Cas9: a new and promising player in gene therapy. J. Med. Genet. 52 (2015), 289–296.
41. Cyranoski, D., Chinese scientists to pioneer first human CRISPR trial. Nature 535 (2016), 476–477.
42. Weber, J., et al. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 13982–13987.
43. Yin, H., et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34 (2016), 328–333.
44. Smurnyy, Y., et al. DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells. Nat. Chem. Biol. 10 (2014), 623–625.
45. Cong, L., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
46. Mandal, P.K., et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15 (2014), 643–652.
47. Vannocci, T., et al. A new cellular model to follow Friedreich's ataxia development in a time-resolved way. Dis. Model. Mech. 8 (2015), 711–719.
48. Tai, D.J., et al. Engineering microdeletions and microduplications by targeting segmental duplications with CRISPR. Nat. Neurosci. 19 (2016), 517–522.
49. Liu, J., et al. CRISPR/Cas9 facilitates investigation of neural circuit disease using human iPSCs: mechanism of epilepsy caused by an SCN1A loss-of-function mutation. Transl. Psychiatry, 6, 2016, e703.
50. Park, C.Y., et al. Reversion of FMR1 methylation and silencing by editing the triplet repeats in Fragile X iPSC-derived neurons. Cell Rep. 13 (2015), 234–241.
51. Xu, P., et al. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in beta-thalassemia-derived iPSCs. Sci. Rep., 5, 2015, 12065.
52. Wang, J., Quake, S.R., RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 13157–13162.
53. Zhen, S., et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem. Biophys. Res. Commun. 450 (2014), 1422–1426.
54. Alkelai, A., et al. A role for TENM1 mutations in congenital general anosmia. Clin. Genet. 90 (2016), 211–219.
55. Gaj, T., et al. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31 (2013), 397–405.
56. Wu, Y., et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 13 (2013), 659–662.
57. Yang, H., et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154 (2013), 1370–1379.
58. Long, C., et al. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345 (2014), 1184–1188.
59. Lin, S.R., et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol. Ther. Nucleic Acids, 3, 2014, e186.
60. Zuckermann, M., et al. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat. Commun., 6, 2015, 7391.
61. Swiech, L., et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33 (2015), 102–106.
62. Xue, W., et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514 (2014), 380–384.
63. Carroll, K.J., et al. A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 338–343.
64. Sanchez-Rivera, F.J., et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516 (2014), 428–431.
65. Nelson, C.E., et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351 (2016), 403–407.
66. Hwang, W.Y., et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 31 (2013), 227–229.
67. Li, W., et al. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat. Biotechnol. 31 (2013), 684–686.
68. Yoshimi, K., et al. ssODN-mediated knock-in with CRISPR-Cas for large genomic regions in zygotes. Nat. Commun., 7, 2016, 10431.
69. Wang, F., et al. Targeted gene disruption in Xenopus laevis using CRISPR/Cas9. Cell Biosci., 5, 2015, 15.
70. Crispo, M., et al. Efficient generation of myostatin knock-out sheep using CRISPR/Cas9 technology and microinjection into zygotes. PLoS One, 10, 2015, e0136690.
71. Wang, X., et al. Generation of gene-modified goats targeting MSTN and FGF5 via zygote injection of CRISPR/Cas9 system. Sci. Rep., 5, 2015, 13878.
72. Yan, Q., et al. Generation of multi-gene knockout rabbits using the Cas9/gRNA system. Cell Regener., 3, 2014, 12.
73. Honda, A., et al. Single-step generation of rabbits carrying a targeted allele of the tyrosinase gene using CRISPR/Cas9. Exp. Anim. 64 (2015), 31–37.
74. Wang, K., et al. Efficient generation of myostatin mutations in pigs using the CRISPR/Cas9 system. Sci. Rep., 5, 2015, 16623.
75. Wang, X., et al. One-step generation of triple gene–targeted pigs using CRISPR/Cas9 system. Sci. Rep., 6, 2016, 20620.
76. Niu, Y., et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156 (2014), 836–843.
77. Kang, Y., et al. CRISPR/Cas9-mediated Dax1 knockout in the monkey recapitulates human AHC-HH. Hum. Mol. Genet. 24 (2015), 7255–7264.
78. Park, C.Y., et al. Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell 17 (2015), 213–220.
79. Yang, Y., et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat. Biotechnol. 34 (2016), 334–338.
80. Ran, F.A., et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520 (2015), 186–191.
81. Zuris, J.A., et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33 (2015), 73–80.
82. Liang, X., et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J. Biotechnol. 208 (2015), 44–53.
83. Sun, W., et al. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew. Chem. Int. Ed. Engl. 54 (2015), 12029–12033.
84. Peng, R., et al. Potential pitfalls of CRISPR/Cas9-mediated genome editing. FEBS J. 283 (2016), 1218–1231.
85. Sander, J.D., et al. Zinc Finger Targeter (ZiFiT): an engineered zinc finger/target site design tool. Nucleic Acids Res. 35 (2007), W599–W605.
86. Hsu, P.D., et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31 (2013), 827–832.
87. Naito, Y., et al. CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. Bioinformatics 31 (2015), 1120–1123.
88. Bae, S., et al. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30 (2014), 1473–1475.
89. Labun, K., et al. CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering. Nucleic Acids Res. 44 (2016), W272–276.
90. Heigwer, F., et al. E-CRISP: fast CRISPR target site identification. Nat. Methods 11 (2014), 122–123.
91. Kim, S., et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24 (2014), 1012–1019.
92. Prykhozhij, S.V., et al. Correction: CRISPR MultiTargeter: a web tool to find common and unique CRISPR single guide RNA targets in a set of similar sequences. PLoS One, 10, 2015, e0138634.
93. Liu, H., et al. CRISPR-ERA: a comprehensive design tool for CRISPR-mediated gene editing, repression and activation. Bioinformatics 31 (2015), 3676–3678.
94. Chari, R., et al. Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach. Nat. Methods 12 (2015), 823–826.
95. Moreno-Mateos, M.A., et al. CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nat. Methods 12 (2015), 982–988.
96. Singh, R., et al. Cas9-chromatin binding information enables more accurate CRISPR off–target prediction. Nucleic Acids Res., 43, 2015, e118.
97. Doench, J.G., et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34 (2016), 184–191.
98. Kalebic, N., et al. CRISPR/Cas9-induced disruption of gene expression in mouse embryonic brain and single neural stem cells in vivo. EMBO Rep. 17 (2016), 338–348.
99. Peng, D., Tarleton, R., EuPaGDT: a web tool tailored to design CRISPR guide RNAs for eukaryotic pathogens. Microb. Genomes, 1, 2015, e000033.
100. Brandl, C., et al. Creation of targeted genomic deletions using TALEN or CRISPR/Cas nuclease pairs in one-cell mouse embryos. FEBS Open Biol. 5 (2015), 26–35.
101. Xiong, X., et al. CRISPR/Cas9 for human genome engineering and disease research. Annu. Rev. Genomics Hum. Genet. 17 (2016), 131–154.
102. Lee, A.Y., Lloyd, K.C., Conditional targeting of Ispd using paired Cas9 nickase and a single DNA template in mice. FEBS Open Biol. 4 (2014), 637–642.
103. Dong, C., et al. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res. 118 (2015), 110–117.
104. Heckl, D., et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 32 (2014), 941–946.
105. Aubrey, B.J., et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 10 (2015), 1422–1432.
106. Yang, Y., et al. Naive induced pluripotent stem cells generated from beta-thalassemia fibroblasts allow efficient gene correction with CRISPR/Cas9. Stem Cells Transl. Med., 5, 2016, 267.
107. Dow, L.E., et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat. Biotechnol. 33 (2015), 390–394.